Purpose: To prospectively investigate the prognostic significance of p21 and p53 expression in diffuse large B-cell lymphoma in the context of the U.S. Intergroup trial comparing conventional cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy to rituximab-CHOP (R-CHOP) induction, with or without maintenance rituximab.
. In the hematologic malignancies, hypermethylation of the p21Waf1 promoter region resulting in decreased p21 expression has been correlated with adverse outcomes in acute lymphoblastic leukemia (11) , and deletion or loss of expression of the p21Waf1 gene has been associated with aggressive mantle cell lymphoma variants (12) .
Mutations of the TP53 gene have been identified in as many as 20% of all diffuse large B-cell lymphomas (DLBCL) and have been associated with poor prognosis in patients treated with conventional chemotherapy (13, 14) . Strong immunohistochemical nuclear staining for p53 with absent p21 staining has been associated with TP53 gene alterations and has been used as an imperfect surrogate for mutated TP53 in some studies (14, 15) . When assessed by immunohistochemical staining, p53 alone is not a consistent predictor of clinical outcome in DLBCL (14, (16) (17) (18) .
The addition of the anti-CD20 monoclonal antibody rituximab to standard chemotherapy such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has improved clinical outcomes for young and old patients with DLBCL (19) (20) (21) . Studies have shown that rituximab modulates the prognostic significance of some biomarkers, reflecting a selective benefit for the addition of rituximab to CHOP chemotherapy for some subsets of DLBCL and not others (22) (23) (24) (25) . In a companion trial to the U.S. Intergroup phase III study comparing CHOP to rituximab-CHOP (R-CHOP) and maintenance rituximab to observation in patients older than 60 years with DLBCL, we prospectively investigated potential biological markers of prognosis (20) . In addition to a previously reported analysis of BCL6 and BCL2 (25) , we prospectively investigated the prognostic significance of p53 and p21. In this correlative study, we observed that p21 expression measured by immunohistochemical staining was a favorable independent prognostic indicator in older patients with DLBCL treated with R-CHOP but not among those treated with CHOP chemotherapy. Furthermore, our analysis showed that the addition of rituximab to CHOP had differential effects on outcomes for p21-positive and p21-negative patients, benefiting the p21-positive patients selectively.
Materials and Methods
Eligibility. Eastern Cooperative Oncology Group (ECOG) or Southwest Oncology Group patients enrolled in the phase III U.S. Intergroup trial (E4494, C9793, S4494) comparing CHOP to R-CHOP, followed by a second randomization to either maintenance rituximab or observation, were eligible for this study (20) . Adequate pathologic material was required for participation as previously described (25) . All participants signed informed consent forms as approved by the Institutional Review Boards of each participating institution in accordance with the Declaration of Helsinki. This analysis includes all cases for which material was submitted for p53 and p21 staining.
Clinical trial. Patients with the age of 60 y or older were stratified according to number of International Prognostic Index risk factors and then randomized to treatment with either six to eight cycles of CHOP alone or with rituximab administered 7 and 3 d before the 1st cycle and then 2 d before cycles 3, 5, and 7 as previously described (20) . Complete or partial responders then underwent a second randomization 3 wk after induction chemotherapy to either observation or maintenance rituximab administered as 4 weekly infusions (375 mg/m 2 ) every 6 mo for a total of 4 cycles.
Immunohistochemical studies. Sections (5 μm) from biopsy specimens were stained with hematoxylin and eosin to confirm the presence of lymphoma in the tissue to be studied. Immunohistochemical staining was done using heat-induced antigen retrieval as previously described (26) . Commercial mouse monoclonal antibodies to p53 (DAKO M7001/clone DO-7) and p21/WAF1 (Oncogene Research Products 0P64) were used in this study. Staining for Bcl-6 and Bcl-2 was described previously (25) .
Pathology review. All cases underwent tertiary review as previously described (20) . Immunohistochemical staining was reviewed by at least two members of the expert panel with discordant cases resolved by a consensus review of the panel or a third reviewer. Cases were scored as entirely negative, 1% to 9%, 10% to 20%, 21% to 50%, and >50% positive. Consistent with previously published series, p53 and BCL2 positive cases were defined as those in which >50% of the large neoplastic cells stained positively for the protein of interest (16, 17, 22, 25, 27, 28) .
Previous studies on p21 staining in solid tumors have used a cutoff of either 2% or 5% to define positivity. Among series of mantle cell lymphomas, the mean number of positive cells has been in the low single digits (12, 29) . Similar to the largest series of NHL, we found that <20% of cases had >10% immunoreactive cells (15) . Given the large number of cases in which <10% of cells were scored
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as positive and the difficulties inherent in distinguishing between cases with very low levels of staining, cases with any definitive staining of large neoplastic cells for p21 were considered to be positive for purposes of the presented analysis. A similar definition of positivity was applied to the BCL6 analysis as previously reported (25) . This cut point (no staining versus staining of any large neoplastic cells for BCL6) has now been validated by the Lunenburg Lymphoma Biomarker Consortium (30) .
Statistical plan. Fisher's exact test and Wilcoxon ranksum test were used to compare patient characteristics between groups. Failure-free survival was defined as the time from randomization to relapse, nonprotocol treatment, or death. Overall survival was measured as the time from randomization to death from any cause. The KaplanMeier method was used to estimate failure-free and overall survival (25, 31) . The prognostic significance of all biomarkers was evaluated for all patients and according to induction and maintenance therapy using univariable (Fisher's exact test; log rank) and multivariable (Cox proportional hazard regression models) analyses. The multivariable analyses controlled for the effect of the International Prognostic Index (low/low-intermediate versus high-intermediate/high), BCL2 expression status, and BCL6 expression status. Using similar methods, outcomes for CHOP versus R-CHOP according to p21 or p53 expression were compared to evaluate the predictive value of the biomarkers. All Ps were based on two-sided tests and were adjusted for multiple comparisons.
Whereas maintenance rituximab improved outcomes after CHOP but not R-CHOP, methods applied in the published analysis of the U.S. Intergroup trial were used to compare induction treatments without the confounding effect of maintenance rituximab (20, 25) . Rather than exclude all patients who received MR from the analysis, which would increase the proportion of nonresponders relative to the whole population and underestimate the failure-free and overall survival, an unbiased estimate was obtained by applying a weighted Cox regression model as previously described (32, 33) . This analysis provides prognostic information for each biomarker in the context of induction therapy without the potentially confounding effect of maintenance rituximab. Accordingly, the effect of maintenance rituximab has been removed in all analyses presented in this manuscript.
Results
p21 and p53 protein expression. The U.S. Intergroup trial accrued 632 patients, including 544 with complete International Prognostic Index data. A total of 387 patients were enrolled from the participating cooperative groups (ECOG and Southwest Oncology Group). Within this subset of patients, there were 197 cases with adequate pathology material and interpretable p53 and p21 staining. The primary reason for exclusion of cases was insufficient pathology material, either material was not submitted for this study or the submitted tissue was judged to be insufficient by the expert hematopathology panel.
p21 positivity was defined as the presence of any large neoplastic cells that were immunoreactive for nuclear p21 by immunohistochemical staining. In just more than half (108 or 55%) of the 197 cases, p21 was scored as positive. In most (67% or 62%) cases scored as positive, <10% of the cells were immunoreactive (Fig. 1 ). There were 22 (11%) cases with 10% to 20% immunoreactive neoplastic cells; in 16 (8%) cases, 21% to 50% neoplastic cells stained with the anti-p21 reagent. Only 3 (2%) cases had >50% of the large neoplastic cells stain for p21. Consistent with the largest non-Hodgkin lymphoma series, only 20% of cases had >10% of the neoplastic cells stain positively for p21 (15) . The remaining 90 cases (46%) were completely negative for p21 expression.
Only 45 (23%) of cases were p53 positive. In additional analyses, p53immunoreactivity associated with p21 negativity served as a possible surrogate for mutated p53.
Patient characteristics. Patient characteristics in this correlative study were representative of the larger U.S. Intergroup trial (Table 1) . When the p21+ and p21-subgroups were compared, no significant differences were observed in the distribution of patient characteristics (all P > 0.4). A similar percentage of patients in the CHOP and R-CHOP arms were p21+ (56% versus 54%, respectively; P = 0.9), and patient characteristics were also balanced between treatment arms. Similarly, no significant differences in patient characteristics were observed according to treatment with R-CHOP or CHOP by p21 status.
When analyzed according to p53 expression and treatment, patient characteristics were also similar between groups (Supplementary Table S1), with the exception of age; p53 positive cases treated with R-CHOP were slightly older than those treated with CHOP (69 versus 66; P = 0.04). p21 expression and clinical outcome. With a median follow-up of 6.85 years, p21 predicted failure-free survival when patients were analyzed according to induction arm. For patients treated with R-CHOP, the 5-year estimated failure-free survival was superior for p21-positive patients relative to p21-negative patients (61% ± 6% versus 38% ± 7%; P = 0.05; Fig. 2 ). In contrast, no significant differences in failure-free survival were detected between outcomes for p21-positive and p21-negative cases treated with CHOP (failure-free survival, 24% ± 7% versus 37% ± 7%; P = 0.6). Overall response rates (complete remission/partial r e m i s s i o n ) f o r p 2 1 -p o s i t i v e a n d p 2 1 -n e g a t i v e patients treated with CHOP or R-CHOP did not differ significantly (P = 0.4 and P = 0.8, respectively). Figure 3 illustrates the impact of rituximab on clinical outcomes according to p21 status. p21-positive but not p21-negative patients benefited from the addition of rituximab to CHOP. The 5-year failure-free survival for p21-positive patients treated with R-CHOP compared with CHOP induction was 61% ± 7% versus 24% ± 7% (P = 0.01). A trend was observed toward a 5-year overall survival benefit for p21-positive patients treated with R-CHOP compared with CHOP (64%± 6% versus 47% ± 7%; P = 0.1). Table 2 shows the relative risk estimates from the multivariable analysis by treatment. The multivariable analysis adjusted for the effects of International Prognostic Index and BCL6 and BCL2 expression. Among patients treated with R-CHOP, p21 expression was an independent determinant of improved 5-year failure-free survival (relative risk, 0.3; P = 0.001) and overall survival (relative risk, 0.3; P = 0.003). In contrast, p21 expression was not a determinant of clinical outcome in patients treated with CHOP. No significant interactions were detected between BCL2, BCL6, and p21 for either failure-free or overall survival (P = 0.55; P = 0.40). Furthermore, no significant interaction was identified between p21 and International Prognostic Index (P > 0.9 for failure-free and overall survival).
Consistent with our previous report and with nearly 7 years of follow-up, BCL6 expression retained its favorable prognostic significance among patients treated with CHOP but was not an independent predictor of either failure-free or overall survival among patients treated with R-CHOP. Although BCL6 has been reported to repress transcription of the gene that encodes p21, no correlation was found between p21 immunoreactivity and BCL6 staining (P = 0.7) in our clinical specimens (5) . Among the BCL6-positive subset of cases studied, p21 status predicted clinical outcome among patients treated with R-CHOP (failure-free survival, P = 0.01; overall survival, P = 0.05) but not CHOP (failure-free survival, P = 0.9; overall survival, P = 0.9). There were too few BCL6-negative cases to do a similar analysis.
Because this study was stratified by International Prognostic Index and not by p21 status, a multivariable analysis was also done to evaluate the effect of treatment, controlling for p21 expression. In a proportional hazards model, among p21-positive patients, the addition of rituximab to CHOP improved failure-free survival [relative risk, 0.5; 95% confidence interval (95% CI), 0.2-1.0; P = 0.05] after adjusting for International Prognostic Index and BCL6 and BCL2 expression. No such treatment effect was seen among p21-negative patients (relative risk, 0.9; 95% CI, 0.4-1.7; P = 0.7).
p53 expression and clinical outcome. In the univariable analysis, strong p53 expression (>50% of large neoplastic cells; 24% of all cases) was not a significant prognostic indicator when all cases were considered (P > 0.9) or when cases were analyzed according to induction treatment (Supplementary Table S2 ). Whereas other groups have shown p53 overexpression to be associated with inferior outcomes (16, 28) , we also did a multivariable analysis that controlled for the effect of International Prognostic Index and BCL6 and BCL2 expression and found no prognostic significance for p53 expression on clinical outcomes for patients treated with CHOP or R-CHOP. No association between p53 positivity and p21 immunostaining was observed (P = 0.99).
p53-positive/p21-negative phenotype. In keeping with previous reports, the p53-positive/p21-negative phenotype was used as a surrogate marker of mutated TP53 forms to further investigate the prognostic significance of p53 in this trial (16, 28) . Only 20 patients (10%) had a p53-positive/p21-negative phenotype, whereas the remaining 177 patients (90%) had alternate p53/p21 phenotypes, but there were no significant differences in clinical outcomes for these subgroups. Furthermore, when analyzed according to p53/p21 phenotype and induction treatment, no significant differences in clinical outcomes were shown (Supplementary Table S2 ).
Discussion
Expression of p21 protein was a powerful predictor of clinical outcomes in patients with DLBCL treated with R-CHOP chemotherapy on the U.S. Intergroup trial. This observation was independent of BCL6 or BCL2 expression and International Prognostic Index risk group in multivariable analysis. In contrast, p21 expression was not predictive of clinical outcome among patients treated with CHOP alone. The addition of rituximab to standard CHOP improved clinical outcomes in p21-immunoreactive cases selectively, suggesting that rituximab has beneficial biological effects on survival pathways active in p21-positive cases.
p21 is multifaceted, having many biological functions that are context dependent, including tumor suppressor and oncogenic activities (4). p21 inhibits cell cycle progression through its inhibition of cyclin-dependent kinase-cyclin complexes and proliferating cell nuclear antigen (34, 35) . Although expression of p21 is known to be under the regulatory control of p53, it is also regulated by p53-independent mechanisms. p21 modulates apoptosis, regulates transcription of genes important in cell cycle progression and senescence, and affects DNA repair processes. In turn, a variety of transcription factors, ubiquitin ligases, and protein kinases regulate transcription, stability, and cellular localization of p21. Studies in mouse lymphoma models suggest that p21 may also function as an oncogene, possibly related to its antiapoptotic activity (36) (37) (38) . Activation of multiple signaling pathways, including phosphoinositide 3-kinase/Akt and Raf/mitogenactivated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase has been shown to upregulate p21 in nonlymphoid model systems (39) (40) (41) (42) (43) . Lenalidomide, a thalidomide analogue with activity in relapsed and refractory DLBCL (44), histone deacetylase inhibitors, and the proteasome inhibitor bortezomib have all been reported to upregulate p21 in lymphoma cell lines (45) (46) (47) . Future studies will elucidate the precise role p21 plays in DLBCL.
Our finding that p21-expression identifies a subgroup that benefits from rituximab raises new questions about how the anti-CD20 antibody facilitates cell death in p21-expressing DLBCL. Recent studies show that rituximab downregulates p38 mitogen-activated protein kinase, NF-κB, extracellular signal-regulated kinase 1/2, and PI3/ Akt survival pathways contributing to the sensitization of drug resistant lymphoma cells to chemotherapy-induced apoptosis (48) . The selective effect of rituximab on p21 expressing cases may relate, at least in part, to its effects on the mitogen-activated protein kinase and/or Akt kinase pathways (48, 49) . Expression of p21 may be a marker of hyperactivation of these pathways (39) (40) (41) (42) (43) , which may predict sensitivity to rituximab. Alternatively, high levels of p21 may sensitize lymphomas to rituximab more directly in an as yet unknown fashion. This effect does not seem to relate to proliferative activity because there were no significant association between p21 and Ki-67 staining in this study (P = 0.67; data not shown).
The small percentage of positive cells scored in this series and in other lymphoma and solid tumor studies is not inconsistent with the significant biological role being postulated for p21. Immunohistochemistry likely underestimates p21 expression as evidenced by Western blotting in a series of mantle cell lymphomas (12) . In actively proliferating cells, p21 is short lived, also contributing to the relatively small number of immunostaining cells detected in paraffin-embedded tissue.
In contrast to p21, p53 expression did not emerge as a significant prognostic indicator in this study. Previous studies examining the prognostic significance of p53 in DLBCL have yielded variable results (14, 16, 17, 28) . Mutations of TP53, particularly in the DNA-binding regions of the molecule, have been associated with adverse outcomes in DLBCL patients treated with CHOP-like chemotherapy (13, 14) . Some studies have shown concordance between the presence of TP53 mutations and the p53-positive/p21-negative phenotype by immunohistochemistry, suggesting that it may be used as a surrogate, albeit an imperfect one, for mutated TP53 status (14, 15) . Despite this association, the p53-positive/p21-negative phenotype has not predicted clinical outcome in most studies, including this series (14) (15) (16) . Differences between immunohistochemical studies may be attributable to differences in patient characteristics, cutoffs used for scoring, and immunohistochemical techniques (50) . In addition, the sample size of the p53-positive/p21-negative phenotype (∼10% of all cases) may have been too small to detect a difference in our study.
Changes in the prognostic significance of immunohistochemical markers in DLBCL treated with R-CHOP rather than CHOP likely reflect the impact of rituximab on growth and survival mechanisms, including those that relate to p21, BCL6, and BCL2. Data presented in this study coupled with published laboratory studies show p21 to be at the intersection of cell cycle regulation, proliferation, and apoptotic pathways and suggest that rituximab-related effects on clinical outcome may be functionally linked to p21 activity for a subset of cases. Confirmation that p21 status is predictive of clinical outcome among R-CHOP-treated patients in larger data sets is needed. Similarly, the apparent selective benefit of rituximab therapy to p21-expressing cases treated with CHOP chemotherapy requires validation. Although the cell of origin classification is an important biomarker for distinct biological subsets of DLBCL, other biological subgroups dependent on specific growth and survival pathways have been identified and more will likely follow. Therapy that is tailored specifically to the unique biology of these individual subcategories of DLBCL is likely to have the greatest impact.
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